Primo Biotechnology
Primo Biotechnology develops targeted radiopharmaceuticals to provide precise clinical information for precision medicine and radioligand theranostics. The company conducts end-to-end clinical development in Taiwan, covering preclinical studies, IND submissions, clinical network coordination, manufacturing, commercialization, and distribution. Its core technologies include molecular imaging agents and radioligand therapy/radiodiagnostic compounds, with expertise in radiopharmaceutical discovery and regulatory pathways. Primo serves hospitals, clinical researchers, and commercial partners deploying radiotheranostic agents in clinical practice.
Primo Biotechnology
Primo Biotechnology develops targeted radiopharmaceuticals to provide precise clinical information for precision medicine and radioligand theranostics. The company conducts end-to-end clinical development in Taiwan, covering preclinical studies, IND submissions, clinical network coordination, manufacturing, commercialization, and distribution. Its core technologies include molecular imaging agents and radioligand therapy/radiodiagnostic compounds, with expertise in radiopharmaceutical discovery and regulatory pathways. Primo serves hospitals, clinical researchers, and commercial partners deploying radiotheranostic agents in clinical practice.